Anne C. Fleischer (Global VP of Consumer Engagement & New Business Models at Novo Nordisk) and Henrijette Richter (Managing Partner at Sofinnova Partners) join Jeppe Høier on stage at the EUCVC Summit 2025 to explore how corporates and VCs are shaping the next wave of health innovation.
From personalized treatments powered by AI, to the crucial role of data rights and trust in scaling digital health, Anne and Henrijette share hard-won insights on how pharma and venture can collaborate without killing speed or innovation.
They discuss the “impatience economy,” where patients increasingly demand fast, personalized solutions, and why collaboration across startups, corporates, and investors is essential to turn science into scalable business models.
🎧 Here’s what’s covered
00:10 The next wave of health innovation — AI, deep tech, and strategic investment.
01:00 Beyond the pill — Novo Nordisk’s vision for personalized, AI-driven patient care.
03:00 Investor lens — what separates fundable AI health companies from “science projects.”
04:00 Data rights & distribution — why exclusivity and integration pathways are critical.
05:00 Corporate–startup collaboration — Novo Nordisk’s partner platform for scaling innovation.
06:00 Scaling globally from day one — why diversified data and pharma channels matter.
07:00 The “translator role” — people who speak both startup and corporate languages.
08:00 The impatience economy — consumerization of health and the risks of losing trust.
09:00 Looking ahead — specificity for patients as the next frontier in health innovation.